Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Whooping Cough Test Clears FDA With Additional Claim

NEW YORK (GenomeWeb) – DiaSorin Molecular announced today that its assay to detect pathogens that cause pertussis, or whooping cough, has received clearance from the US Food and Drug Administration for an additional claim.

The Simplexa Bordetella Direct test kit detects and differentiates two gram-negative pathogens — Bordetella pertussis and Bordetella parapertussis — in fresh nasopharyngeal swab samples without a requirement for nucleic acid extraction. It provides results in about one hour. The moderate complexity test runs on the firm's Liaison MDx system, which also runs FDA-cleared assays for Clostridium difficile, herpes simplex virus 1 and 2, and Group B Strep.

The kit was initially cleared last year for detection from frozen nasopharyngeal swab specimens. According to a DiaSorin spokesperson, additional fresh samples were collected from five geographically diverse sites and compared to another FDA-cleared Bordetella pertussis nucleic acid amplification test.  The B. pertussis target showed 100 percent positive agreement and approximately 98 percent negative agreement. The B. parapertussis target, meanwhile, showed 100 percent positive and negative agreement compared to bi-directional sequencing.

Pertussis is a highly infectious illness that in severe cases can lead to hypoxia or death. Despite vaccinations, cases have increased in the US recently. Worldwide, in 2014 there were were 24 million cases and 160,700 deaths from pertussis in children under 5 years old, according to research published in Lancet.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.